Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Reexamination Certificate
2006-05-02
2006-05-02
Falk, Anne-Marie (Department: 1635)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
C435S252300, C536S023100, C514S04400A
Reexamination Certificate
active
07037718
ABSTRACT:
The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for mutant purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells. The present invention provides nucleotide sequences encoding mutantE. coliderived purine nucleoside phosphorylase proteins which can be used in conjunction with an appropriate substrate to produce toxins which impair abnormal cell growth. The invention provides for delivery of the toxin by generation within target cells or by administration and delivery to the cells from without.
REFERENCES:
patent: 5552311 (1996-09-01), Sorscher et al.
patent: 0 392 745 (1990-10-01), None
patent: 0 415 731 (1991-03-01), None
patent: PCT/US96/10250 (1996-06-01), None
patent: WO 96/40238 (1996-12-01), None
Maynes, JT et al. Design of an adenosine phosphorylase by active site modification of murine purine nucleoside phosphorylase. Biochemical Journal, 1999, vol. 344, pp. 585-592.
Anderson (2001) Editorial Excitement in Gene Therapy! Human Gene Therapy, vol. 12, pp. 1483-1484.
Andreansky et al. (1996) The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors Proc. Natl. Acad. Sci. USA, vol. 93, pp. 11313-11318.
Beck et al. (1995) The Thymidine Kinase/Ganciclovir-Mediated “Suicide” Effect is Variable in Different Tumor Cells Human Gene Therapy, vol. 6, pp. 1525-1530.
Bischoff et al. (1996) An Adenovirus Mutant That Replicates Selectively in p53-Deficient Human Tumor Cells Science, vol. 274, pp. 373-376.
Cacciapuoti et al. (1994) Purification and Characterization of Extremely Thermophilic and Thermostable 5'-Methylthioadenosine Phosphorylase from the ArchaeonSulfolobus solfataricusThe Journal of Biological Chemistry, vol. 269, No. 40, pp. 24762-24769.
Cacciapuoti et al. (1996) Extremely thermophilic and thermostable 5'-methylthioadenosine phosphory from the archaeonSulfolobus solfataricusGene Cloning and amino acid sequence determination Eur. J. Biochem., vol. 239, pp. 632-637.
Dilber et al. (1997) Gap Junctions Promoe the Bystander Effect of Herpes Simplex Virus Thymidine Kinasein VivoCancer Research, No. 57, pp. 1523-1528.
Dix et al. (2001) Minireview: Does the Antitumor Adenovirus ONYX-015/d11520 Selectively Target Cells Defect in the p53 Pathway? Journal of Virology, pp. 5443-5447.
Doronin et al. (2001) Tissue-Specific, Tumor-Selective, Replication-Competent Adenovirus Vector for Cancer Gene Therapy Journal of Virology, pp. 3314-3324.
Elshami et al. (1996) Gap junctions play a role in the ‘bystander effect’ of the herpes simplex virus thymidine kinase/ganciclovir system in vitro Gene Therapy 3, pp. 85-92.
Freeman et al. (1993) The “Bystander Effect”: Tumor Regression When a Fraction of the Tumor Mass is Genetically Modified Cancer Research 53, pp. 5274-5283.
GE et al. (1997) Transduction of Cytosine Deaminase Gene Makes Rat Glioma Cells Highly Sensitive to 5-Fluorocytosine Int. J. Cancer, No. 71, pp. 675-679.
Gnant et al. (1999) Systemic Administration of a Recombinant Vaccinia Virus Expressing the Cytosine Deaminase Gene and Subsequent Treatment with 5-Fluorocytosine Leads to Tumor-specific Gene Expression and Prolongation of Survival in Mice Cancer Research 59, pp. 3396-3403.
Hall et al. (1998) p53-dependent cell death/apoptosis is required for a productive adenovirus infection Nature Medicine, vol. 4, No. 9, pp. 1068-1072.
Heise et al. (1997) ONYX-015, and EIB gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents Nature Medicine, vol. 3, No. 6, pp. 639-645.
Heise et al. (1999) Intravenous Administration of ONYX-015, a Selectively Replicating Adenovirus, Induces Antitumoral Efficacy Cancer Research 59, pp. 2623-2628.
Huang et al. (1987) Phosphorolytic Cleavage of 2-Fluoroadenine from 9-B-D-Arabinofuranosyl-2-Fluoroadenine byEscherichia ColiA Pathway for 2-Fluoro-Atp Production Biochemical Pharmarology, vol. 30, No. 18, pp. 2945-2950.
Huber et al. (1994) Metabolism of 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase Proc. Natl. Acad. Sci. USA, vol. 91, pp. 8302-8306.
Imaizumi et al. (1998) Bystander Tumoricidal Effect and Gap Junctional Communication in Lung Cancer Cell Lines American Journal of Respiratory Cell and Molecular Biology,vol. 18, No. 2, pp. 205-212.
Jaffe (1975) Nucleoside Analogs as Antiparasitic Agents Annals of the New York Acamdemy of Sciences, Chemistry, Biology, and Clinical Uses of Nucleoside Analogs, vol. 255, pp. 306-316.
Johnson et al. (2002) Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents Cancer Cell, vol. 1, pp. 325-337.
Khuri et al. (2000) A controlled trial of intratumoral ONYXA-015, a selectively-replicating adenovirus, in combination with cisplating and 5-fluorouracil in patients with recurrent head and neck cancer Nature Medicine, vol. 6, No. 8, pp. 879-885.
Lane (1998) Killing tumor cells with viruses-a question of specificity Nature Medicine, vol. 4, No. 9,, pp. 1012-1013.
Lemmon et al. (1997) Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment Gene Therapy 4, pp. 791-796.
Linke (1998) Has the smart bomb been diffused? Nature, vol. 395, pp. 13 and 15.
Lowe (1997) Progress of the smart bomb cancer virus. A mutant adenovirus capable of preferentially destroying cancer cells shows promise in preclinical studies (639-645), Nature Medicine, vol. 3, No. 6, pp. 606-607.
Ma et al. (2002) Cells Designed to Delivery Anticancer Drugs by Apoptosis Cancer Research 62, pp. 1382-1387.
Nemunaitis et al. (2001) Phase II Trial of Intratumoral Administrative on ONY-015, a Replication-Selective Adenovirus, in Patients With Refractory head and Neck Cancer Journal of Clinical Oncology, vol. 19, No. 2, pp. 289-298.
Nemunaitis et al. (2001) Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasability and biological activity, Gene Therapy, Abstract, 2 pages.
Pennisi (1998) Training Viruses to Attack Cancers Coffey et al. (1998) Reovirus Therapy of Tumors with Activatred Ras Pathway Science, vol. 282, pp. 1244-1246 and 1332-1334.
Ram et al. (1993)In SituRetroviral-mediated Gene Transfer for the Treatment of Brain Tumors in Rats Cancer Research 53, pp. 83-88.
Rothmann et al. (1998) Replication of ONYX-015, a Potential Anticancer Adenovirus, is Independent of p53 Status in Tumor Cells Journal of Virology, vol. 72, pp. 9470-9478.
Sacco et al. (1996) Partial regression,yet incomplete eradication of mammary tumors in transgenic mice by retrovirally mediated HSVtk transfer ‘in vivo’ Gene Therapy 3, pp. 1151-1156.
Searle et al. (1998) Adenoviral vectors: not to be sneezed at Gene Therapy 5, pp. 725-727.
Shinoura et al. (1999) Highly Augmented Cytopathic Effect of a Fiber-mutant EIB-defective Adenovirus for Gene Therapy of Gliomas Cancer Research 59, pp. 3411-3416.
Wildner et al. (1999) Therapy of Colon Cancer with Oncolytic Adenovirus is Enhanced by the Additionof Herpes Simplex Virus-thymidine kinaseCancer Research 59, pp. 410-413.
Yeh et al. (1997) Advances in adenoviral vectors: from genetic engineering to their biology the FASEB Journal, vol. 11, pp. 615-623.
Allen (1989) Stealth™ Liposomes: Avoiding Retinculoendothelial Uptake Liposomes in the Therapy of Infectious Diseases and Cancer, pp. 405-415.
Barankiewicz and Jezewska (1975) Inosine-Guanosine and Adenosine Phosphorylase Activities in Hepatopancreas ofHelix pomatia(Gastropoda) Comp. Biochem. Physiol., vol. 54B, pp. 239-242.
Bennett et al. (1984) Mode of Action of 2-amino-6-chloro-1-deazapurine Biochemical Pharmacology, vol. 33, No. 2, pp. 261-271.
Bohman et al. (1983) Mechanism of Cytostatic Action o
Ealick Steven E.
Parker William B.
Secrist, III John A.
Sorscher Eric J.
Angell Jon Eric
Cornell Research Foundation Inc.
Falk Anne-Marie
Gifford, Krass, Groh Sprinkle, Anderson & Citkowski, P.C.
Southern Research Institute
LandOfFree
Mutant purine nucleoside phosphorylase proteins and cellular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutant purine nucleoside phosphorylase proteins and cellular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutant purine nucleoside phosphorylase proteins and cellular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3613585